Halozyme Therapeutics (HALO) Tops Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $108.17 +1.93%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.21), $0.07 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $39 million versus the consensus estimate of $38.37 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
- Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
